Found this on our competitor bb Advt6 Nov 2023 08:53
Aptamer Group RNSToday 08:48
Aptamer Group (APTA) develop Optimers for diagnostic reagents and pharmaceutical solutions. Optimers specifically, as opposed to Aptamers more generally, are alternatives to antibodies but based on DNA or RNA oligonucleotide molecules, whereas Affimers are based on human stefin.
They have just posted a rather downbeat trading update, at least in relation to 2023 revenue …
https://www.lse.co.uk/rns/APTA/trading-update-kftpmni53fk0vy2.html
However, the ‘Technical’ section of the RNS is quite interesting, particularly …
“Secondly, we have made great progress in building a body of data further supporting our Optimer-based pharmaceuticals for gene therapy delivery and precision chemotherapy. This opens opportunities for the specific delivery of chemotherapeutics to site of action; for example, using these techniques to target specific tumours could reduce the amount of drug administered and thereby minimise side effects. We have successfully built the drug conjugates for oligonucleotide, radionuclide, and chemotherapeutic delivery, with the results showing selective delivery and gene knockdown or cell killing, respectively. This work will form the bedrock of technical data to attract larger pharmaceutical partners. Results from this work will be disseminated, as delivered, over the next 12 months.”
They are at least 2-3 years behind AVCT, even if they can get any funding.
But now valued at ~£6m, perhaps an opportunity, strategically, to acquire a potentially competing platform. Unless, of course, we have a high degree of certainty in our near-term outcome.